Altimmune (ALT) Non Operating Income (2010 - 2026)
Altimmune (ALT) reported Non Operating Income of -$152000.0 for Q1 2026, down 1113.33% year-over-year from $15000.0 in Q1 2025, and down 462.96% on a QoQ basis from -$27000.0 in Q4 2025.
Altimmune (ALT) has 17 years of Non Operating Income data on file, last reported at -$152000.0 in Q1 2026.
- Quarterly Non Operating Income fell 1113.33% year-over-year to -$152000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 134.84% YoY) and the FY2025 annual result came in at -$190000.0, down 495.83% from the prior year.
- Non Operating Income retreated to -$152000.0 in Q1 2026 per ALT's latest filing, from -$27000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.9 million in Q2 2023 and bottomed at -$6.4 million in Q4 2024.
- The 5-year median for Non Operating Income is $15000.0 (2025), against an average of -$168411.8.
- Peak annual rise in Non Operating Income reached 7684.0% in 2023, while the deepest fall reached 2358.06% in 2023.
- Tracing ALT's Non Operating Income over 5 years: stood at -$217000.0 in 2022, then plunged by 2358.06% to -$5.3 million in 2023, then fell by 19.59% to -$6.4 million in 2024, then soared by 99.58% to -$27000.0 in 2025, then slumped by 462.96% to -$152000.0 in 2026.
- Per Business Quant, the three latest ALT Non Operating Income figures stand at -$152000.0 (Q1 2026), -$27000.0 (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | -152,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -152,000.00 |
| Dec 31, 2025 | -27,000.00 |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | -92,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | -6.38 Mn |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | -76,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | -5.33 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 1.95 Mn |
| Mar 31, 2023 | 1.69 Mn |
| Dec 31, 2022 | -217,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 25,000.00 |
| Mar 31, 2022 | 69,000.00 |
| Dec 31, 2021 | -81,000.00 |
| Sep 30, 2021 | -306,000.00 |
| Jun 30, 2021 | 37,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | 17,672.00 |
| Sep 30, 2020 | 29,218.00 |
| Jun 30, 2020 | 72,272.00 |
| Mar 31, 2020 | 175,226.00 |
| Dec 31, 2019 | -655,679.00 |
| Sep 30, 2019 | -23,734.00 |
| Jun 30, 2019 | 163,996.00 |
| Mar 31, 2019 | 46,749.00 |
| Dec 31, 2018 | 6,688.00 |
| Sep 30, 2018 | 877,524.00 |
| Jun 30, 2018 | -5.20 Mn |
| Mar 31, 2018 | 1.83 Mn |
| Dec 31, 2017 | 621,693.00 |
| Sep 30, 2017 | 10,786.00 |
| Jun 30, 2017 | -92,826.00 |
| Mar 31, 2017 | -61,714.00 |
| Dec 31, 2016 | 7,451.00 |
| Sep 30, 2016 | -5,537.00 |
| Jun 30, 2016 | -6,110.00 |
| Mar 31, 2016 | 4,119.00 |
| Dec 31, 2015 | 1,543.00 |
| Sep 30, 2015 | -691.00 |
| Jun 30, 2015 | -1,911.00 |
| Mar 31, 2015 | 9,196.00 |
| Dec 31, 2014 | 299,126.00 |
| Sep 30, 2014 | 80.00 |
| Jun 30, 2014 | -1,912.00 |
| Mar 31, 2014 | 173,131.00 |
| Dec 31, 2013 | -813,893.00 |
| Sep 30, 2013 | 507.00 |
| Jun 30, 2013 | 2,110.00 |
| Mar 31, 2013 | -6,123.00 |
| Dec 31, 2012 | -1.33 Mn |
| Sep 30, 2012 | 1.60 Mn |
| Jun 30, 2012 | 519.00 |
| Mar 31, 2012 | 52,915.00 |
| Dec 31, 2011 | -11,564.00 |
| Sep 30, 2011 | 2.99 Mn |
| Jun 30, 2011 | 643,707.00 |
| Mar 31, 2011 | -11,906.00 |
| Dec 31, 2010 | 15,441.00 |
| Sep 30, 2010 | -93,260.00 |
| Jun 30, 2010 | 29,752.00 |